ADAR1 Capital Management LLC Acquires 43,400 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Key Points

• ADAR1 Capital Management LLC significantly increased its stake in Arrowhead Pharmaceuticals by 336.4%, acquiring an additional 43,400 shares, bringing its total to 56,300 shares valued at $717,000.
• Analysts have issued positive ratings for Arrowhead Pharmaceuticals, with two firms upgrading it to a "strong-buy" status, while the consensus rating remains at "Buy" with a target price of $43.14.
• Despite a reported loss of ($1.26) earnings per share for the last quarter, Arrowhead Pharmaceuticals had revenue of $27.77 million, close to analysts' estimates.

ADAR1 Capital Management LLC boosted its stake in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 336.4% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 56,300 shares of the biotechnology company's stock after purchasing an additional 43,400 shares during the quarter. ADAR1 Capital Management LLC's holdings in Arrowhead Pharmaceuticals were worth $717,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of ARWR. GAMMA Investing LLC raised its holdings in Arrowhead Pharmaceuticals by 297.6% in the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock valued at $28,000 after acquiring an additional 1,628 shares in the last quarter. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals in the 4th quarter valued at $49,000. CWM LLC grew its holdings in shares of Arrowhead Pharmaceuticals by 134.3% during the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after purchasing an additional 2,523 shares during the last quarter. KBC Group NV increased its holdings in shares of Arrowhead Pharmaceuticals by 40.8% in the first quarter. KBC Group NV now owns 7,356 shares of the biotechnology company's stock valued at $94,000 after purchasing an additional 2,132 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in Arrowhead Pharmaceuticals in the 1st quarter worth approximately $133,000. 62.61% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the stock. HC Wainwright reaffirmed a "buy" rating and set a $80.00 target price on shares of Arrowhead Pharmaceuticals in a report on Tuesday, September 2nd. Wall Street Zen cut Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Friday, July 18th. Royal Bank Of Canada cut their price target on shares of Arrowhead Pharmaceuticals from $40.00 to $38.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Citigroup reduced their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Finally, Chardan Capital reaffirmed a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research note on Monday, August 11th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of "Buy" and a consensus target price of $43.14.

Arrowhead Pharmaceuticals Stock Up 3.9%

Shares of ARWR stock traded up $1.08 during trading hours on Friday, hitting $29.08. 2,716,522 shares of the company were exchanged, compared to its average volume of 2,925,274. Arrowhead Pharmaceuticals, Inc. has a 52 week low of $9.57 and a 52 week high of $29.34. The company has a current ratio of 4.87, a quick ratio of 4.87 and a debt-to-equity ratio of 0.39. The business has a 50 day moving average of $18.78 and a two-hundred day moving average of $16.23. The company has a market capitalization of $4.02 billion, a PE ratio of -22.72 and a beta of 1.00.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.94) by ($0.32). The business had revenue of $27.77 million during the quarter, compared to analysts' expectations of $29.01 million. During the same quarter last year, the company earned ($1.38) earnings per share. Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, insider James C. Hamilton sold 15,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $25.00, for a total value of $375,000.00. Following the completion of the transaction, the insider directly owned 247,122 shares in the company, valued at $6,178,050. This trade represents a 5.72% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders sold 25,000 shares of company stock worth $575,000 over the last ninety days. Corporate insiders own 4.30% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.